GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenxbio Inc (NAS:RGNX) » Definitions » Short Interest

RGNX (Regenxbio) Short Interest


View and export this data going back to 2015. Start your Free Trial

What is Regenxbio Short Interest?

Short Interest can be expressed as a percentage by dividing the number of shares sold short by the total number of outstanding shares.

Due to the license agreement change with our data vendor, Short Interest related data is no longer available on GuruFocus website.

Competitive Comparison of Regenxbio's Short Interest

For the Biotechnology subindustry, Regenxbio's Short Interest, along with its competitors' market caps and Short Interest data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Regenxbio's Short Interest Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Regenxbio's Short Interest distribution charts can be found below:

* The bar in red indicates where Regenxbio's Short Interest falls into.


;
;

Regenxbio Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Regenxbio Inc (NAS:RGNX) » Definitions » Short Interest
Comparable Companies
STOK TSHA ALDX SANA EYPT CELC RNAC ALT UPB RAPP VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
RB0:Germany
Address
9804 Medical Center Drive, Rockville, MD, USA, 20850
Website
https://www.regenxbio.com
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.
Executives
Argeris N Karabelas director
Curran Simpson officer: SVP of Technical Operations C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Kenneth T. Mills director, officer: See Remarks C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Steve Pakola officer: Chief Medical Officer C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Vittal Vasista officer: See Remarks C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Jennifer Zachary director 2000 GALLOPING HILL ROAD, KENILWORTH NJ 07033
Allan M. Fox director, 10 percent owner C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Jean Bennett director C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
George V Migausky director C/O DYAX CORP., 300 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Patrick J. Christmas officer: Senior VP, General Counsel C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Hayden Donald J Jr director C/O AMICUS THERAPEUTICS, INC., 1 CEDAR BROOK DRIVE, CRANBURY NJ 08512
Olivier Danos officer: Chief Scientific Officer C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850
Luke M Beshar director 550 HILLS DRIVE, 3RD FLOOR, BEDMINSTER NJ 07921
Stephen Yoo officer: Chief Medical Officer C/O REGENXBIO INC,, 9600 BLACKWELL ROAD, SUITE 210, ROCKVILLE MD 20850
Alexandra Glucksmann director C/O REGENXBIO INC., 9804 MEDICAL CENTER DRIVE, ROCKVILLE MD 20850